Meeting News Coverage

Six biomarkers linked to prediction of CVD in type 2 diabetes

Researchers have confirmed associations between six biomarkers for the prediction of cardiovascular disease in type 2 diabetes, according to data presented at EASD 2013.

“We’re also reporting what we think is a novel association between interleukin-15 as a predictor of incident CVD in type 2 diabetes and these interesting associations of apolipoprotein C-III and soluble RAGE (sRAGE) with incident CVD, which were unexpected and need further investigation,” Helen C. Looker, MBBS, of the National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, said during a presentation.

The study included patients with type 2 diabetes from the Go-DARTS (n=1,204), the Scania Diabetes Registry (n=666), MONICA/KORA (n=308), IMPROVE (n=94) and 60-year Old Stockholm Study (n=64), according to abstract data.

Looker and colleagues examined 42 biomarkers, but only 16 were studied further for their improved prediction of CVD.

“Of the biomarkers we tested, many showed association with incident CVD, but when picking a panel, we found most of the improvement in prediction could be cut down to six markers in addition to clinical covariates,” Looker said

Those with the most significant association with CVD included:

  • N-terminal pro-B-type natriuretic peptide (OR=1.72; 95% CI, 1.49-1.99);
  • Apolipoprotein C-III (OR=1.26; 95% CI, 1.10-1.43);
  • sRAGE (OR=0.82; 95% CI, 0.73-0.91);
  • High-sensitivity troponin T (OR=0.85; 95% CI, 0.77-0.94);
  • IL-6 (OR=1.16; 95% CI, 1.05-1.29); and
  • IL-15 (OR=1.17; 95% CI, 1.06-1.29).

“We feel these findings are already relatively robust because they’ve been found across several studies, but we clearly need to do some replication in other cohorts, and that is ongoing,” Looker said.

For more information:

Brady I. Oral Presentation #9. Presented at: the 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 24-27, 2013; Barcelona, Spain.

Disclosure: This study was supported by SUMMIT Consortium IMI-2008/115006 and Hoffmann-La Roche.

Researchers have confirmed associations between six biomarkers for the prediction of cardiovascular disease in type 2 diabetes, according to data presented at EASD 2013.

“We’re also reporting what we think is a novel association between interleukin-15 as a predictor of incident CVD in type 2 diabetes and these interesting associations of apolipoprotein C-III and soluble RAGE (sRAGE) with incident CVD, which were unexpected and need further investigation,” Helen C. Looker, MBBS, of the National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, said during a presentation.

The study included patients with type 2 diabetes from the Go-DARTS (n=1,204), the Scania Diabetes Registry (n=666), MONICA/KORA (n=308), IMPROVE (n=94) and 60-year Old Stockholm Study (n=64), according to abstract data.

Looker and colleagues examined 42 biomarkers, but only 16 were studied further for their improved prediction of CVD.

“Of the biomarkers we tested, many showed association with incident CVD, but when picking a panel, we found most of the improvement in prediction could be cut down to six markers in addition to clinical covariates,” Looker said

Those with the most significant association with CVD included:

  • N-terminal pro-B-type natriuretic peptide (OR=1.72; 95% CI, 1.49-1.99);
  • Apolipoprotein C-III (OR=1.26; 95% CI, 1.10-1.43);
  • sRAGE (OR=0.82; 95% CI, 0.73-0.91);
  • High-sensitivity troponin T (OR=0.85; 95% CI, 0.77-0.94);
  • IL-6 (OR=1.16; 95% CI, 1.05-1.29); and
  • IL-15 (OR=1.17; 95% CI, 1.06-1.29).

“We feel these findings are already relatively robust because they’ve been found across several studies, but we clearly need to do some replication in other cohorts, and that is ongoing,” Looker said.

For more information:

Brady I. Oral Presentation #9. Presented at: the 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 24-27, 2013; Barcelona, Spain.

Disclosure: This study was supported by SUMMIT Consortium IMI-2008/115006 and Hoffmann-La Roche.

    See more from European Association for the Study of Diabetes